natgillin/translations-raw huggingface dataset:
When clinically appropriate direct change from monotherapy to the fixed combinations may be considered:  Karvezide 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;  Karvezide 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Karvezide 150 mg/12.5 mg.  Karvezide 300 mg/25 mg may be administered in patients insufficiently controlled by Karvezide 300 mg/12.5 mg. 
Kadar je klinično primerno, se lahko razmisli o prehodu iz monoterapije na kombinirano zdravljenje: Zdravilo Karvezide 150 mg/12,5 mg je namenjeno bolnikom, pri katerih se zvišan krvni tlak med zdravljenjem samo s hidroklorotiazidom ali samo s 150 mg irbesartana ni dovolj znižal.
How to store Karvezide 
Shranjevanje zdravila Karvezide
Although not specifically studied with the Karvezide, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide. 
Posebnih študij z zdravilom Karvezide ni, kljub temu pa povratnega zvišanja krvnega tlaka pri bolnikih, ki so jemali bodisi irbesartan bodisi hidroklorotiazid, po prenehanju jemanja zdravila niso opazili.
Excipient with known effect: Each film-coated tablet contains 89.5 mg of lactose (as lactose monohydrate). 
Ena filmsko obložena tableta vsebuje 89,5 mg laktoze (v obliki laktoze monohidrata).
 if you suffer from heart problems  if you suffer from liver problems  if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure). 
če imate primarni aldosteronizem (stanje, povezano s čezmernim izločanjem hormona aldosterona, kar povzroči zastajanje natrija in posledično zvišanje krvnega tlaka)
Karvezide 150 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets. 
Karvezide 150 mg/12,5 mg tablete so na voljo v pretisnih omotih s 14, 28, 56 ali 98 tabletami.
headache 
Glavobol
Excipient with known effect: Each film-coated tablet contains 53.3 mg of lactose (as lactose monohydrate). 
Ena filmsko obložena tableta vsebuje 53,3 mg laktoze (v obliki laktoze monohidrata).
Karvezide 300 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets. 
Karvezide 300 mg/12,5 mg tablete so na voljo v pretisnih omotih s 14, 28, 56 ali 98 tabletami.
Common side effects (may affect up to 1 in 10 people): nausea/vomiting abnormal urination fatigue dizziness (including when getting up from a lying or sitting position) blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine). 
krvne preiskave lahko pokažejo zvišanje vrednosti encima, ki kaže na delovanje mišic in srca (encim kreatin-kinaza), ali zvišanje vrednosti snovi, ki so merilo delovanja ledvic (dušik sečnine v krvi, kreatinin).
Excipient with known effect: Each tablet contains 26.65 mg of lactose (as lactose monohydrate). 
Ena tableta vsebuje 26,65 mg laktoze (v obliki laktoze monohidrata).
Each film-coated tablet of Karvezide 300 mg/25 mg contains 300 mg irbesartan and 25 mg hydrochlorothiazide. 
Ena Karvezide 300 mg/25 mg filmsko obložena tableta vsebuje 300 mg irbesartana in 25 mg hidroklorotiazida.
Vistor hf. 
UV-žarkom.
Karvezide 150 mg/12.5 mg tablets. 
Karvezide 150 mg/12,5 mg tablete
A total of 697 patients were randomized in a 2:1 ratio to either irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to irbesartan 150 mg and systematically force titrated (before assessing the response to the lower dose) after one week toirbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg, respectively. 
Skupaj je bilo randomiziranih 697 bolnikov v razmerju 2:1, bodisi na irbesartan/hidroklorotiazid 150 mg/12,5 mg bodisi na irbesartan 150 mg.
Karvezide 300 mg/12.5 mg tablets. 
Karvezide 300 mg/12,5 mg tablete
What Karvezide contains  The active substances are irbesartan and hydrochlorothiazide. 
Zdravilni učinkovini sta irbesartan in hidroklorotiazid.
Because no information is available regarding the use of Karvezide during breast-feeding, Karvezide is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant. 
Podatkov o uporabi zdravila Karvezide med dojenjem ni na voljo, zato uporaba zdravila Karvezide med dojenjem ni priporočljiva.
Warnings and precautions Talk to your doctor before taking Karvezide and if any of the following apply to you:  if you get excessive vomiting or diarrhoea  if you suffer from kidney problems or have a kidney transplant  if you suffer from heart problems if you suffer from liver problems  if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure). 
če začnete prekomerno bruhati ali dobite hudo drisko če imate težave z ledvicami ali presajeno ledvico če imate težave s srcem če imate težave z jetri če imate sladkorno bolezen če imate eritematozni lupus (znan tudi kot lupus ali sistemski eritematozni lupus)
Karvezide is unlikely to affect your ability to drive or use machines. 
Možnost, da bi zdravilo Karvezide vplivalo na sposobnost za upravljanje vozil in strojev je majhna.
Karvezide 300 mg/25 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. 
Karvezide 300 mg/25 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženimi tabletami.
Each film-coated tablet contains 300 mg of irbesartan and 25 mg of hydrochlorothiazide. 
Ena filmsko obložena tableta vsebuje 300 mg irbesartana in 25 mg hidroklorotiazida.
cough 
Kašelj
These lesions were not observed in macaques;  decreases in serum potassium due to hydrochlorothiazide and partly prevented when hydrochlorothiazide was given in combination with irbesartan. 
znižanje kalija v serumu med uporabo hidroklorotiazida, ki je bilo med kombiniranim dajanjem z irbesartanom manj izrazito.
Karvezide 300 mg/12.5 mg film-coated tablets. 
Karvezide 300 mg/12,5 mg filmsko obložene tablete
Karvezide 150 mg/12.5 mg film-coated tablets. 
Karvezide 150 mg/12,5 mg filmsko obložene tablete
Each tablet of Karvezide 150 mg/12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide. 
Ena Karvezide 150 mg/12,5 mg tableta vsebuje 150 mg irbesartana in 12,5 mg hidroklorotiazida.
Karvezide 150 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. 
Karvezide 150 mg/12,5 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženimi tabletami.
Each tablet of Karvezide 300 mg/12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide. 
Ena Karvezide 300 mg/12,5 mg tableta vsebuje 300 mg irbesartana in 12,5 mg hidroklorotiazida.
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):  kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;  slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit);  stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day. 
ledvične spremembe so se kazale kot blago zvečanje sečnine in kreatinina v serumu ter hiperplazija/hipertrofija jukstaglomerulnega aparata, kar je neposredna posledica interakcije med irbesartanom in sistemom renin-angiotenzin; blago zmanjšanje eritrocitnih parametrov (eritrocitov, hemoglobina in hematokrita);
Karvezide 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide 
Karvezide 300 mg/25 mg filmsko obložene tablete irbesartan/hidroklorotiazid
Karvezide 300 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. 
Karvezide 300 mg/12,5 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženimi tabletami.
Each film-coated tablet of Karvezide 150 mg/12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide. 
Ena Karvezide 150 mg/12,5 mg filmsko obložena tableta vsebuje 150 mg irbesartana in 12,5 mg hidroklorotiazida.
Each film-coated tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide. 
Ena filmsko obložena tableta vsebuje 150 mg irbesartana in 12,5 mg hidroklorotiazida.
Excipient with known effect: Each tablet contains 65.8 mg of lactose (as lactose monohydrate). 
Ena tableta vsebuje 65,8 mg laktoze (v obliki laktoze monohidrata).
Each tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide. 
Ena tableta vsebuje 150 mg irbesartana in 12,5 mg hidroklorotiazida.
Each tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide. 
Ena tableta vsebuje 300 mg irbesartana in 12,5 mg hidroklorotiazida.
Karvezide 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide 
Karvezide 300 mg/12,5 mg tablete irbesartan/hidroklorotiazid
Each film-coated tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide. 
Ena filmsko obložena tableta vsebuje 300 mg irbesartana in 12,5 mg hidroklorotiazida.
Each film-coated tablet of Karvezide 300 mg/12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide. 
Ena Karvezide 300 mg/12,5 mg filmsko obložena tableta vsebuje 300 mg irbesartana in 12,5 mg hidroklorotiazida.
Karvezide 150 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide 
Karvezide 150 mg/12,5 mg filmsko obložene tablete irbesartan/hidroklorotiazid
While this is not documented with Karvezide, a similar effect should be anticipated. 
Podoben učinek bi lahko pričakovali pri zdravljenju z zdravilom Karvezide, čeprav to pri zdravljenju z njim ni bilo dokazano.
Karvezide 300 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide 
Karvezide 300 mg/12,5 mg filmsko obložene tablete irbesartan/hidroklorotiazid
The trough to peak effects measured by cuff during office visits were 68% and 76% for Karvezide 150 mg/12.5 mg and Karvezide 300 mg/12.5 mg, respectively. 
Pri merjenju z manšeto v ambulanti je bilo pri bolnikih, ki so jemali zdravilo Karvezide 150 mg/12,5 mg, to razmerje 68%, pri tistih, ki so dobivali zdravilo
You may need to have blood checks if you take: potassium supplements salt substitutes containing potassium potassium sparing medicines or other diuretics (water tablets) some laxatives medicines for the treatment of gout therapeutic vitamin D supplements medicines to control heart rhythm medicines for diabetes (oral agents or insulins) carbamazepine (a medicine for the treatment of epilepsy). 
zdravila za uravnavanje srčnega ritma zdravila za zdravljenje sladkorne bolezni (peroralni pripravki ali insulin) karbamazepin (zdravilo za zdravljenje epilepsije)
EU/1/98/085/008 - 14 tablets EU/1/98/085/004 - 28 tablets EU/1/98/085/005 - 56 tablets EU/1/98/085/010 - 56 x 1 tablets EU/1/98/085/006 - 98 tablets 
EU/1/98/085/028 - 56 x 1 tableta EU/1/98/085/026 - 84 tablet
Package leaflet: Information for the patient Karvezide 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide 
Navodilo za uporabo Karvezide 300 mg/25 mg filmsko obložene tablete irbesartan/hidroklorotiazid
EU/1/98/085/007 - 14 tablets EU/1/98/085/001 - 28 tablets EU/1/98/085/002 - 56 tablets EU/1/98/085/009 - 56 x 1 tablets EU/1/98/085/003 - 98 tablets 
EU/1/98/085/009 - 56 x 1 tableta EU/1/98/085/003 - 98 tablet
Package leaflet: Information for the patient Karvezide 150 mg/12.5 mg tablets irbesartan/hydrochlorothiazide 
Navodilo za uporabo Karvezide 150 mg/12,5 mg tablete irbesartan/hidroklorotiazid
Package leaflet: Information for the patient Karvezide 150 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide 
Navodilo za uporabo Karvezide 150 mg/12,5 mg filmsko obložene tablete irbesartan/hidroklorotiazid
Package leaflet: Information for the patient Karvezide 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide 
Navodilo za uporabo Karvezide 300 mg/12,5 mg tablete irbesartan/hidroklorotiazid
Package leaflet: Information for the patient Karvezide 300 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide 
Navodilo za uporabo Karvezide 300 mg/12,5 mg filmsko obložene tablete irbesartan/hidroklorotiazid
What Karvezide looks like and contents of the pack Karvezide 300 mg/25 mg film-coated tablets are pink, biconvex, oval-shaped, with a heart debossed on one side and the number 2788 engraved on the other side. 
Karvezide 300 mg/25 mg filmsko obložene tablete so rožnate barve, bikonveksne in ovalne oblike.
Karvezide with food and drink Karvezide can be taken with or without food. 
Zdravilo Karvezide skupaj s hrano in pijačo
EU/1/98/085/011 - 14 tablets EU/1/98/085/012 - 28 tablets EU/1/98/085/029 - 30 tablets EU/1/98/085/013 - 56 tablets EU/1/98/085/014 - 56 x 1 tablets EU/1/98/085/021 - 84 tablets EU/1/98/085/032 - 90 tablets EU/1/98/085/015 - 98 tablets 
EU/1/98/085/014 - 56 x 1 tableta EU/1/98/085/021 - 84 tablet
The European Commission issued a decision on 20 December 2012. 
Evropska komisija je sklep izdala 20. decembra 2012.
The company wanted the authorisation to be recognised in the Czech Republic , Denmark, Estonia, Hungary, Lithuania, Latvia, Norway, Poland, Sweden, Slovenia and Slovakia (the ‘concerned Member States'). 
Družba je želela, da se dovoljenje za promet z zdravilom prizna v Češki republiki, na Danskem, v Estoniji, na Madžarskem, v Litvi, Latviji, na Norveškem, Poljskem, Švedskem, v Sloveniji in na Slovaškem (v „zadevnih državah članicah”).
This means that the use of the active substance has been well-established in the European Union for over ten years. 
To pomeni, da je bila uporaba zdravilne učinkovine v Evropski uniji dobro uveljavljena že več kot deset let.
‘Idiopathic' means that the cause of the urticaria is not known. 
„Idiopatska” pomeni, da vzrok urtikarije ni znan.
The initial authorisation was based on a wellestablished use application. 
Prvotno dovoljenje je temeljilo na vlogi na podlagi dobro uveljavljene uporabe.
Why was Loraxin reviewed? 
Zakaj je bilo zdravilo Loraxin pregledano?
However, the Member States were not able to reach an agreement and the Finnish medicines regulatory agency referred the matter to the CHMP for arbitration on 23 December 2011. 
Vendar države članice niso mogle doseči soglasja, zato je finska regulativna agencija za zdravila 23. decembra 2011 zadevo napotila na CHMP v arbitražo.
On 21 June 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Loraxin. 
Evropska agencija za zdravila je 21. junija 2012 zaključila arbitražni postopek po nesoglasju med državami članicami Evropske unije (EU) glede izdaje dovoljenja za promet z zdravilom Loraxin.
The grounds for the referral were the concerns of the Swedish and Polish medicines agencies that its safety and benefits could not be ascertained on the basis of the data that were submitted. 
Razlogi za napotitev so bili pomisleki švedske in poljske agencije za zdravila, da na podlagi predloženih podatkov ni mogoče dokazati varnosti in koristi zdravila.
The active substance in Loraxin, loratadine, is an antihistamine. 
Zdravilna učinkovina v zdravilu Loraxin, loratadin, je antihistaminik.
For well-established use applications, data from the published literature on medicines with the same active substance are used to show the benefits and safety of a medicine. 
Vloge na podlagi dobro uveljavljene uporabe temeljijo na podatkih iz objavljene literature o zdravilih z isto zdravilno učinkovino, ki naj bi dokazali koristi in varnost zdravila.
Loraxin is a medicine used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy such as hay fever or allergy to dust mites) and long-term idiopathic urticaria (itchy rash). 
Loraxin je zdravilo, ki se uporablja za lajšanje simptomov alergijskega rinitisa (vnetja nosne votline, ki ga povzroči alergija, na primer seneni nahod ali alergija na pršice) in kronične idiopatske urtikarije (srbečega izpuščaja).
The Committee therefore recommended that the marketing authorisation granted in Finland should not be recognised in other Member States of the EU. 
Zato je priporočil, da se dovoljenje za promet z zdravilom, ki je bilo izdano na Finskem, ne prizna v drugih državah članicah EU.
It works by blocking receptors for histamine, a substance in the body that causes allergic symptoms. 
Deluje tako, da zavira receptorje, na katere se veže histamin, tj. snov v telesu, ki povzroča alergijske simptome.
What is Loraxin? 
Kaj je zdravilo Loraxin?
Therefore, the Committee concluded that the benefits of the medicine could not be shown to outweigh its risks and recommended that the marketing authorisation should not be granted in the concerned Member States. 
Zato je zaključil, da ni mogoče dokazati, da koristi zdravila odtehtajo z njim povezana tveganja, in priporočil, da se dovoljenje za promet z zdravilom v zadevnih državah članicah ne izda.
Vitabalans Oy submitted an application for Loraxin for mutual recognition, on the basis of an initial authorisation granted by Finland on 31 August 2010. 
Družba Vitabalans Oy je predložila vlogo za pridobitev dovoljenja za promet z zdravilom Loraxin po postopku z medsebojnim priznavanjem na podlagi prvotnega dovoljenja za promet z zdravilom, izdanega 31. avgusta 2010 na Finskem.
The marketing authorisation in Finland should also be suspended. 
Prav tako je treba začasno umakniti dovoljenje za promet z zdravilom na Finskem.
The CHMP noted that the published data that was submitted with this application were limited, and not sufficient to support this well-established use application for Loraxin. 
CHMP je ugotovil, da so bili objavljeni podatki, ki so bili predloženi v podporo vlogi, omejeni in niso zadostovali za utemeljitev te vloge za pridobitev dovoljenja za promet z zdravilom Loraxin na podlagi dobro uveljavljene uporabe.
In addition, the Committee recommended that the marketing authorisation for Loraxin in Finland should be suspended. 
Prav tako je priporočil začasen umik dovoljenja za promet z zdravilom Loraxin na Finskem.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that it was not possible to show that the benefits of Loraxin outweigh its risks based on the data submitted by the company. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da na podlagi podatkov, ki jih je predložila družba, ni mogoče dokazati, da koristi zdravila Loraxin odtehtajo z njim povezana tveganja.
Tell your doctor straight away if: 
Zdravniku takoj povejte, če:
• Treatment is continued until you get the desired response. 
• Zdravljenje se nadaljuje, dokler ne dobite želenega odziva.
In your body: 
V vašem telesu:
If this happens, your doctor will need to examine you as soon as possible. 
Če se to zgodi, vas mora čim prej pregledati zdravnik.
Follow the instructions exactly, as it may differ from your past experience. 
Navodila natančno upoštevajte, saj se morda razlikujejo od vaših izkušenj iz preteklosti.
• Put it aside for later use. 
• Shranite ga za kasnejšo uporabo.
• This may take up to 5 weeks. 
• To lahko traja do 5 tednov.
These women are usually infertile. 
Te ženske so ponavadi neplodne.
Complete a partial injection (only when needed). 
Dokončajte z delno injekcijo (le po potrebi).
• Give yourself the injection at the same time each day. 
• Zdravilo si injicirajte vsak dan ob istem času.
It may be acceptable to extend the duration of stimulation in any one cycle to up to 5 weeks. 
Sprejemljivo je podaljšanje trajanja stimulacije v katerem koli ciklusu vse do 5 tednov.
Tres Cantos E-28760 Madrid Spain 
Tres Cantos E-28760 Madrid Španija
Other in-use storage times and conditions are the responsibility of the user. 
Za drugačen čas in pogoje shranjevanja je odgovoren uporabnik.
Do not use this medicine if any of the above apply to you. 
Ne uporabljajte tega zdravila, če kar koli od zgoraj naštetega velja za vas.
The mean residence time is approximately 5 hours. 
Srednji čas zadrževanja je približno 5 ur.
The frequency categories used are: very common (≥1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Uporabljene so naslednje kategorije pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) , neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Pergoveris must not be used when an effective response cannot be obtained, such as: 
Zdravila Pergoveris se ne sme uporabljati, kadar ni mogoče doseči učinkovitega odziva, kot pri:
Zone Industrielle de l'Ouriettaz CH-1170 Aubonne Switzerland 
Zone Industrielle de l'Ouriettaz CH-1170 Aubonne Švica
This helps the women to become pregnant. 
To ženski pomaga zanositi.
Wash your hands with soap and water (Fig. 1). 
Roke si umijte z milom in vodo (sl. 1).
EXP Shelf life after first use: 28 days 
EXP Rok uporabnosti po prvi uporabi: 28 dni
After the injection 8.1. 
Po injiciranju 8.1.
This medicine is used to stimulate the development of follicles (each containing an egg) in your ovaries. 
To zdravilo se uporablja za stimulacijo razvoja foliklov (vsak vsebuje eno jajčece) v vaših jajčnikih.
The best time to have sex is on the day of the hCG injection and the day after. 
Najboljši čas za spolni odnos je na dan injiciranja hCG in in naslednji dan.
Please contact your doctor. 
Pokličite zdravnika.
In these trials the ovulation rate per cycle was 70-75%. 
V teh preskušanjih je bila stopnja ovulacije na ciklus 70-75 %.
It should be noted however, that pregnancy itself as well as OHSS also carries an increased risk of thromboembolic events. 
Vendar pa je treba omeniti, da tudi nosečnost sama, kot tudi OHSS prinaša povečano tveganje za trombembolične dogodke.
The doctor might ask you to stop using Pergoveris. 
Zdravnik vas bo morda prosil, da prenehate uporabljati zdravilo Pergoveris.
Safety and effectiveness of this medicinal product in elderly patients have not been established. 
Varnost in učinkovitost tega zdravila pri starejših bolnikih nista bili dokazani.
IF 
ČE
Verify you select the prescribed pen. 
Preverite, da ste izbrali predpisani peresnik.
Treatment should recommence in the next cycle at a dose of FSH lower than that of the previous cycle. 
Ponovno zdravljenje v naslednjem ciklusu se mora začeti z nižjim odmerkom FSH kot v predhodnem ciklusu.
Chemical and physical in-use stability has been demonstrated for 28 days at 25°C. 
Kemična in fizikalna stabilnost med uporabo je bila dokazana za 28 dni pri 25 °C.
Push the plunger until the air bubbles are gone. 
Potiskajte bat, dokler zračni mehurčki ne izginejo.
They might ask you to stop using this medicine (see in section 4. under “Most serious side effects”). 
Morda vas bodo prosili, da prenehate uporabljati to zdravilo (glejte poglavje 4 „Najresnejši neželeni učinki“).
• If no droplet is seen, follow the instructions on the following page. 
• Če kapljice ne vidite, ravnajte po navodilih na naslednji strani.
Contact your doctor straight away if you notice any of the below listed side effects. 
Takoj se posvetujte z zdravnikom, če opazite katerega od spodaj naštetih neželenih učinkov.